PDS BIOTECHNOLOGY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.9 USD | +6.62% |
|
-13.95% | -41.65% |
| Mar. 28 | B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating | MT |
| Mar. 27 | Empire Metals targets key milestones in Australia | AN |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 275K | Capitalization | 99.77M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | -63M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 363 x |
| P/E ratio 2024 * |
-1.95
x | P/E ratio 2025 * |
-1.8
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on PDS Biotechnology Corporation
More recommendations
More press releases
| 1 day | +6.62% | ||
| 1 week | -13.95% | ||
| Current month | -26.77% | ||
| 1 month | -39.01% | ||
| 3 months | -32.40% | ||
| 6 months | -33.18% | ||
| Current year | -41.65% |
1 week
2.68
3.24
1 month
2.685.00
Current year
2.686.68
1 year
2.6810.27
3 years
2.6817.85
5 years
0.6217.85
10 years
0.6217.85
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Bedu-Addo
FOU | Founder | 59 | 19-03-14 |
| Director of Finance/CFO | 55 | Dec. 03 | |
David Schaaf
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Glover
CHM | Chairman | 65 | 19-04-01 |
Otis Brawley
BRD | Director/Board Member | 64 | 20-11-02 |
Richard Sykes
BRD | Director/Board Member | 79 | 19-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.9 | +6.62% | 1,127,166 |
| 24-04-17 | 2.72 | -2.86% | 610,937 |
| 24-04-16 | 2.8 | -0.71% | 717,504 |
| 24-04-15 | 2.82 | -11.60% | 1,320,659 |
| 24-04-12 | 3.19 | -5.34% | 595,599 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.72
USD
Average target price
14.4
USD
Spread / Average Target
+429.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.65% | 99.77M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- PDSB Stock
